Bone Biologics Corp Stock Price, News & Analysis

Bone Biologics Corporation (NASDAQ: BBLG) has engaged Avania as the Contract Research Organization (CRO) for its upcoming pilot clinical trial of NB1, targeting degenerative disc disease patients undergoing Transforaminal Lumbar Interbody Fusion (TLIF). The multicenter trial will assess the safety and effectiveness of the NB1 bone graft in 30 subjects, anticipated to start in late 2023, pending ethics committee approval from the Monash Health system in Australia. The inclusion of rhNELL-1 in the NB1 device is expected to enhance bone formation. CEO Jeffrey Frelick expressed optimism about moving into human testing with Avania's support.

Bone Biologics Corporation (NASDAQ: BBLG) has announced advancements in their lead product, NB1, utilizing NELL-1 for spinal fusion treatments. The global market for bone graft substitutes is estimated at $3 billion annually, with additional opportunities for osteoporosis and trauma treatments worth $11 billion and $8 billion, respectively. A successful preclinical study on sheep supports NB1's efficacy. The company has secured $5.1 million in recent financing to commence a 30-patient pilot study in Australia in 2023.

On October 13, 2022, WallachBeth Capital LLC announced the closure of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), generating total gross proceeds of $5,100,000. The offering included 3,777,778 units at $1.35 per unit, each comprised of one share of common stock and three different Series warrants. The warrants have various exercise prices and expiration timelines, with some allowing cashless exercises. Underwriters were granted a 45-day option to purchase additional securities. The offering was made under an SEC registration statement that became effective on October 6, 2022.

Bone Biologics Corporation (NASDAQ: BBLG) has completed its underwritten public offering, raising $5,100,000 in gross proceeds. The offering consisted of 3,777,778 units priced at $1.35 each. Each unit includes one share of common stock and several warrants with varying exercise prices. The company intends to utilize the net proceeds for clinical trials, patent maintenance, research organization retention, and general corporate purposes. There is a 45-day option for underwriters to purchase additional shares or warrants.

Bone Biologics Corporation (NASDAQ: BBLG) announced the pricing of an underwritten public offering of 3,777,778 units at $1.35 each, totaling $5,100,000 in gross proceeds. Each unit consists of one share of common stock and three types of warrants with varying exercise prices. The offering, managed by WallachBeth Capital, is set to close on or around October 11, 2022, pending customary conditions. Bone Biologics aims to utilize these funds for the development of its orthobiologic products, primarily focusing on spine fusion.

Bone Biologics Corporation (NASDAQ: BBLG) announced a public offering of 3,777,778 units at $1.35 per unit, raising total gross proceeds of $5.1 million. Each unit includes a share of common stock and various warrants, with exercise prices ranging from $1.35 to $2.16. The offering is expected to close on or about October 11, 2022. An additional 566,666 shares and/or warrants may be offered by underwriters for over-allotments. This offering is registered under Form S-1 and follows SEC approval on October 6, 2022.

Bone Biologics Corporation (NASDAQ: BBLG), specializing in orthobiologic products for spine fusion, will have its president and CEO, Jeffrey Frelick, present at the 2022 Virtual Growth Conference by Maxim Group LLC from March 28-30, 2022. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Interested individuals can view the presentation via the company's investor relations page or directly on the conference's site.

Bone Biologics focuses on innovative bone regeneration solutions, particularly using the Nell-1 protein for spinal fusion and other applications.

Bone Biologics Corporation (NASDAQ: BBLG) has established a supply agreement with MTF Biologics for demineralized bone matrix (DBM), essential for developing a bone graft substitute product using rhNELL-1. This agreement supports a 30-patient pilot study and a subsequent pivotal study in spine fusion patients. CEO Jeff Frelick emphasized the significance of this milestone in the $3 billion spine fusion market, aiming to create a product with unique benefits compared to existing options.